Neurobo Pharmaceuticals Inc

NASDAQ:NRBOUnited States

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies. The Company is engaged in providing therapeutic programs designed to impact a range of indications in coronavirus, neurodegenerative and cardiometabolic disease. Its products include ANA001, Niclosamide, NB-01 and NB-02. The ANA001 is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease. Niclosamide is a potential oral antiviral and anti-inflammatory agent and being studied in a 60-subject Phase II clinical trial conducted in the United States. NB-01 primarily focused on the development of a treatment for painful diabetic neuropathy (PDN). NB-02 has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition.

Contact Information

Headquarters

200 BERKELEY ST., FL 19BOSTON, MA, United States 02116

Phone

857-702-9600

Fax

734-293-0444

Executives

Independent Chairman of the Board

Andrew Koven

President, Interim Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer

Joseph Hooker

Senior Vice President - Operations

Matthew Bardin

Director

Jeong Gu Kang

Independent Director

Jason Groves